Clinical Trial Update: A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy of Xanomeline/Trospium (XT) for cognitive impairment in adults with schizophrenia; recruitment is ongoing and n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Xanomeline/Trospium

Snippet

Sponsor: European Group for Research In Schizophrenia | Conditions: Schizophrenia; Psychosis, Cognitive Impairment | Phase 3 | Status: RECRUITING